case_images: PMC10961462_01
case_images: PMC10961462_02
case_images: The figure shows longitudinal monitoring of EGFR ex19del mutation in the patient described as Case 1. (A) Results of NGS analysis: baseline T0 shows VAF values from both Avenio ctDNA Expanded kit and Sysmex PSS Solid Cancer IVD kit analysis. The data reported from T1 to T5 indicate the VAF values detected by Sysmex PSS Solid Cancer IVD kit panel after the start of treatment with osimertinib. (B) Monitoring of EGFR mutation by RT-PCR Cobas EGFR Mutation Test V2. Time-points were the same as in (A). T0: 02/09/2023; T1: 02/17/2023; T2: 03/09/2023; T3: 04/06/2023; T4: 06/09/2023; T5: 08/24/2023. VAF, Variant Allele Fraction; ISQ, Semi-Quantitative Index.
case_images: fonc-14-1363069-g001.jpg
case_images: PMC10961462_02_fonc-14-1363069-g001.jpg
case_images: f1
case_images: The figure shows subsequent radiological assessments (CT scans) that were performed according to clinical practice for the patient described as Case 1. The sum of target lesions was assessed following RECIST 1.1. CT1: 02/09/2023; CT2: 04/17/2023; CT3: 08/17/2023; CT4: 11/09/2023.
case_images: fonc-14-1363069-g002.jpg
case_images: PMC10961462_02_fonc-14-1363069-g002.jpg
case_images: f2
case_images: The figure shows longitudinal monitoring of EGFR ex19del mutation in the patient described as Case 2. (A) Results of NGS analysis: baseline T0 shows VAF values from both Avenio ctDNA Expanded kit and Sysmex PSS Solid Cancer IVD kit analysis. The data reported as T2 indicate the VAF value detected by Sysmex PSS Solid Cancer IVD kit panel after the start of treatment with osimertinib. (B) Monitoring of EGFR mutation by RT-PCR Cobas EGFR Mutation Test V2. T0 and T2 were the same as in (A), T1 was the first sample after the start of treatment with osimertinib. T0: 09/06/2022; T1: 09/14/2022; T2: 09/26/2022. VAF, Variant Allele Fraction; ISQ, Semi-Quantitative Index.
case_images: fonc-14-1363069-g003.jpg
case_images: PMC10961462_02_fonc-14-1363069-g003.jpg
case_images: f3
case_images: The figure shows subsequent radiological assessments (CT scans) that were performed according to clinical practice for the patient described as Case 2. The sum of target lesions was assessed following RECIST 1.1. CT1: 07/01/2022; CT2: 02/07/2023; CT3: 08/22/2023.
case_images: fonc-14-1363069-g004.jpg
case_images: PMC10961462_02_fonc-14-1363069-g004.jpg
case_images: f4